Molecular Basket Trial In Multiple Malignancies With Common Target Pathway Aberrancies: A Phase II Trial of GSK2256098 and Trametinib in Patients With Advanced Pancreatic Cancer

NCT02428270 Phase 2 COMPLETED

This is a phase 2 study (the second phase in testing a new drug or combination to see how effect the drug or combination is) of investigational drugs GSK2256098 and Trametinib. The purpose of the study is to evaluate the antitumor activity of GSK2256098 and Trametinib in patients with advanced pancreatic cancer.

Details

Lead sponsor	University Health Network, Toronto
Phase	Phase 2
Status	COMPLETED
Enrolment	16
Start date	2016-04
Completion	2022-10-27

Conditions

• Pancreatic Cancer
• Adenocarcinoma

Interventions

• GSK2256098
• Trametinib

Primary outcomes

• Percentage of patients who experience complete response, partial response, or stable disease — 24 weeks

Countries

Canada